EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Laser‐assisted topical delivery of vismodegib reduces hedgehog gene expression in human basal cell carcinomas in vivo

Uffe H Olesen iD, Kristian Kåber Pedersen iD, Katrine Togsverd-Bo iD, Edyta Biskup iD, Anni Linnet Nielsen, Malene Jackerott iD, Gael Clergeaud iD, Thomas L Andresen iD, Merete Haedersdal iD

Lasers in Surgery and Medicine · 2024-03 · 56 (3) · 239-248

DOI: 10.1002/lsm.23766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lasers in Surgery and Medicine, online erschienen am 04.02.2024. Verfasst von Uffe H Olesen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Skin Neoplasms, Basal Cell Carcinoma, Antineoplastic Agents, Lasers, Gas. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemically delivered hedgehog inhibitors including vismodegib and sonidegib are widely used to treat basal cell carcinomas (BCCs). Ablative fractional laser (AFL)‐assisted topical delivery of vismodegib has been demonstrated in preclinical studies. The aim of this explorative clinical study was to evaluate intratumoral vismodegib concentrations and effect on hedgehog pathway gene expression following AFL‐assisted topical vismodegib delivery to BCCs.

Methods

In an open‐label clinical trial, 16 nodular BCCs (in n = 9 patients) received one application of CO 2 ‐AFL (40 mJ/microbeam, 10% density) followed by topical vismodegib emulsion. After 3–4 days, vismodegib concentrations in tumor biopsies ( n = 15) and plasma were analyzed and compared with samples from patients receiving oral treatment ( n = 3). GLI1, GLI2, PTCH1, and PTCH2 expression was determined by quantitative polymerase chain reaction ( n = 7) and GLI1 additionally by in situ hybridization ( n = 3).

Results

Following AFL‐assisted topical administration, vismodegib was detected in 14/15 BCCs and reached a median concentration of 6.2 µmol/L, which compared to concentrations in BCC tissue from patients receiving oral vismodegib (9.5 µmol/L, n = 3, p = 0.8588). Topical vismodegib reduced intratumoral GLI1 expression by 51%, GLI2 by 55%, PTCH1 and PTCH2 each by 73% ( p ≤ 0.0304) regardless of vismodegib concentrations ( p ≥ 0.3164). In situ hybridization demonstrated that GLI1 expression was restricted to tumor tissue and downregulated in response to vismodegib exposure.

Conclusion

A single AFL‐assisted topical application of vismodegib resulted in clinically relevant intratumoral drug concentrations and significant reductions in hedgehog pathway gene expressions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsBasal Cell CarcinomaAntineoplastic AgentsLasers, GasAnilidesPyridinesHumansHedgehog ProteinsZinc Finger Protein GLI1Gene Expression

Stichwörter der Autor:innen

ablative fractional laserbasal cell carcinomaclinical trialemulsion drug formulationlaser-assisted drug deliveryvismodegib

Substanzen

HhAntag691Hedgehog ProteinsZinc Finger Protein GLI1Antineoplastic AgentsAnilidesPyridines

Autor:innen und Institutionen

  • Department of Dermatology, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark.
  • Department of Pathology, Copenhagen University Hospital-Herlev, Herlev, Denmark.
  • Department of Oncology, Copenhagen University Hospital-Herlev, Herlev, Denmark.
  • Leo Pharma A/S, Ballerup, Denmark.
  • Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.

ORCID-Profile: Uffe H Olesen, Kristian Kåber Pedersen, Katrine Togsverd-Bo, Edyta Biskup, Malene Jackerott, Gael Clergeaud, Thomas L Andresen, Merete Haedersdal

Zitieren

APA

Olesen, U. H., Pedersen, K. K., Togsverd-Bo, K., Biskup, E., Nielsen, A. L., Jackerott, M., Clergeaud, G., Andresen, T. L., & Haedersdal, M. (2024). Laser‐assisted topical delivery of vismodegib reduces hedgehog gene expression in human basal cell carcinomas in vivo. Lasers in Surgery and Medicine, 56(3), 239-248. https://doi.org/10.1002/lsm.23766

Vancouver

Olesen UH, Pedersen KK, Togsverd-Bo K, Biskup E, Nielsen AL, Jackerott M, et al. Laser‐assisted topical delivery of vismodegib reduces hedgehog gene expression in human basal cell carcinomas in vivo. Lasers in Surgery and Medicine. 2024;56(3):239-248. doi:10.1002/lsm.23766

BibTeX
@article{Olesen2024,
  author = {Olesen, Uffe H and Pedersen, Kristian Kåber and Togsverd-Bo, Katrine and Biskup, Edyta and Nielsen, Anni Linnet and Jackerott, Malene and Clergeaud, Gael and Andresen, Thomas L and Haedersdal, Merete},
  title = {Laser‐assisted topical delivery of vismodegib reduces hedgehog gene expression in human basal cell carcinomas in vivo},
  journal = {Lasers in Surgery and Medicine},
  year = {2024},
  volume = {56},
  number = {3},
  pages = {239--248},
  doi = {10.1002/lsm.23766}
}
Kostenlos starten →